Every two to five weeks, patients with thalassemia major undergo a life-saving ritual: a mandatory blood transfusion. Without it, severe anemia quickly leads to organ failure, stunted growth and early death. This treatment typically drains up to USD 60,000 per patient each year, overwhelming both household incomes and strained healthcare systems in developing countries.
For families, the burden of this treatment is staggering, stretching emotional and financial resources to breaking point. However, health experts worldwide agree on one critical fact: combining sustained blood donation efforts with effective prevention strategies offers the most promising path to reducing the long-term impact of thalassemia.
Science and Economics of Prevention
Thalassemia is an inherited hemoglobin disorder characterized by reduced or absent synthesis of globin chains, resulting in chronic anemia of varying severity. It is estimated that approximately 5.2% of the world’s population carries a clinically significant hemoglobin variant, contributing to the birth of hundreds of thousands of children with severe hemoglobin disorders each year.
“Available options may include avoiding inter-carrier marriage in certain communities, prenatal diagnosis, preimplantation genetic testing, or preparation for the birth and optimal care of an affected child, depending on the legal, cultural, religious and social context of each country,” states Dr.
Carrier screening offers a detailed genetic profile that supports informed decision making. By taking this step early, couples buy time to explore their options—whether mindful natural conception, IVF with genetic testing, or other personalized family planning approaches.
When both parents are carriers of pathogenic variants associated with thalassemia, each pregnancy has a 25% chance of giving birth to an affected child with a severe form of the disease.
Although the global incidence of thalassemia is estimated at approximately 4.4 cases per 10,000 live births, the disease burden is disproportionately concentrated in the Mediterranean region, the Middle East, Africa, South Asia, Southeast Asia, and southern China. In some regions of Southeast Asia, carrier frequencies have been reported to exceed 20% of the population.
“In Thailand, approximately 100,000 patients with thalassemia major require lifelong blood transfusions and iron-deprivation therapy. The Thai government spends approximately 12-12.6 billion THB (approximately 364-382 million USD) annually to support the long-term management of these patients,” notes Chiprasert University Professor Pornang.
Several countries have demonstrated that population-based prevention programs can significantly reduce the incidence of thalassemia major. Saudi Arabia and Iran, for example, have reported significant reductions in affected births after implementing mandatory premarital screening initiatives.
A study conducted in Thailand showed that incorporating genetic testing into standard thalassemia screening programs generated an estimated net economic benefit of approximately USD 490 per person screened compared with conventional screening approaches alone. These findings suggest that the integration of genetic testing can improve both clinical effectiveness and long-term cost-effectiveness.
“Genetic testing offers a significantly higher diagnostic yield than conventional screening methods because it can simultaneously identify a wide range of pathogenic variants, including rare mutations that may be missed by targeted analyses,” explains Professor Sakorn.
How education empowers communities
Evidence shows that awareness and education play a critical role in improving participation in carrier screening programs. A global survey found that 84.5% of women reported a greater willingness to be screened for thalassemia after receiving information about the health consequences and long-term economic burden associated with the disease. The decision to participate in screening is influenced by a number of practical factors, including accessibility to testing services, affordability, and the timing of screening, particularly before marriage or family planning.
BGI Genomics Global Status of Thalassemia Awareness Report 2023. Image credit: BGI Genomics
Despite advances in screening technologies, public awareness remains insufficient in many areas. Dr Eleftheriou emphasizes that limited access to education, counseling and diagnostic services continues to hamper global prevention efforts, highlighting the need for sustained community engagement and public health initiatives.
Dr Dina Garniasih from Harapan Kita Women’s and Children’s Hospital, Indonesia, advocates the integration of thalassemia screening into routine health care services, particularly during adolescence, premarital health assessments and early pregnancy.
To enhance diagnostic capacity, her institution is working with BGI Genomics, a precision medicine company, to apply high-throughput sequencing technologies to routine diagnostic workflows. In the institution’s experience, this approach has improved diagnostic accuracy and expanded access to molecular testing. The collaboration also aims to improve affordability, support the development of local genome databases, and expand population-level screening programs.
A double march forward
The combination of voluntary blood donation and early screening represents a complementary strategy to address the burden of thalassemia. While blood donation remains essential for patients living with transfusion-dependent disease, screening and prevention programs offer an opportunity to reduce the number of future affected births.
As high-throughput sequencing technologies become more accessible and comprehensive screening programs gain wider political support across Asia and other high-prevalence regions, reducing the burden of thalassemia major is becoming an increasingly realistic public health goal.
